MMMohsen Mohammadi-Sartang

Mohsen Mohammadi-Sartang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mohsen Mohammadi-Sartang has a total of 39 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Association between nutrient patterns and muscle mass, fat mass, and BMI among Iranian adolescents: a cross-sectional study

    by Reza Rahmanian, Ali Razeghi-Pirbasti, Mohsen Shaygantabar, Fatemeh Javaheri-Tafti, Mohammad-Reza Jowshan, Mohsen Mohammadi-Sartang

    Nutrient patterns impact body composition. Adolescents with obesity and overweight are vulnerable to many metabolic diseases. This study aimed to examine t


  • Open Access

    Effects of Non‐Soy Legumes on Body Weight and Body Composition: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials

    by Reza Rahmanian, Mohsen Shaygantabar, Azita Hekmatdoost, Ali Nikparast, Fatemeh Javaheri‐Tafti, Zeinab Ghaeminejad, Andisheh Khoshrang, Alireza Hatami, Mohsen Mohammadi‐Sartang

    Non‐soy legumes are rich in protein, fiber, and phytochemicals that may contribute to the prevention and management of obesity. Previous reviews have not specifically evaluated non‐soy legumes or comprehensive body composition outcomes, highlighting the need for a focused meta‐analysis. This systematic review and meta‐analysis aimed to evaluate the effects of non‐soy legume consumption on body composition parameters in adults, based on evidence from randomized controlled trials. Comprehensive searches were conducted in PubMed, Scopus, Medline, Web of Science, Cochrane Library, and Google Scholar up to January 2024 to identify eligible randomized controlled trials assessing the effects of non‐soy legumes on body weight, body mass index (BMI), waist circumference (WC), and fat mass (FM). Weighted mean differences (WMDs) and 95% confidence intervals (CIs) were calculated using a random‐effects model. Heterogeneity, subgroup analyses, meta‐regression, sensitivity analyses, and publication bias were evaluated using standard statistical methods. Thirty‐six trials met the inclusion criteria. Non‐soy legume consumption significantly reduced WC (WMD: −1.61 cm; 95% CI: −2.06, −1.16; p < 0.001), FM (WMD: −2.00 kg; 95% CI: −2.24, −1.78; p < 0.001), and body weight (WMD: −0.98 kg; 95% CI: −1.63, −0.33; p = 0.003). No significant effect was observed for BMI (WMD: −0.24 kg/m 2 ; 95% CI: −0.50, 0.03; p = 0.08). Subgroup analyses indicated that the effects varied according to intervention duration, participant age, and baseline BMI. Non‐soy legume consumption is associated with significant reductions in body weight, waist circumference, and fat mass, but not BMI. These findings support the potential role of non‐soy legumes in improving anthropometric measures related to obesity, although further high‐quality trials are needed to confirm these effects.

  • The Effect of Different Types of Olive Oil on Glucose Control and Insulin Sensitivity: A GRADE-Assessed Systematic Review and Dose-Response Meta-Analysis of 51 Randomized Controlled Trials

    by Alireza Takhttavous, Kimia Rostampour, Shirin Gerami, Mohsen Mohammadi-Sartang

    Background: Olive oil as food is composed mainly of fatty acids and bioactive compounds with diverse and attractive biological activities that have an inverse relationship with insulin resistance and diabetes-related factors. However, the results of available clinical trials are inconsistent. Therefore, we summarized 51 randomized controlled trials (RCTs) and evaluated the association of olive oil intervention with glycemic control in adults. Methods: A comprehensive literature search of the PubMed, Scopus, and ISI Web of Sciences databases was performed to identify RCTs investigating the effect of different olive oil types on any glycemic profile component. Quantitative data were synthesized using either a fixed or random-effects model, with a weighted mean difference (WMD) and 95% CI for analysis. Results: In the primary search, 2705 articles were found, of which 115 were assessed in full text, and 51 trials (n = 4334 participants) were included in the meta-analysis. We found the consumption of olive oil was not associated with statistically significant changes in blood glucose (WMD = –0.04 mg dL–1; 95% CI, –0.1 to 0.02; P = .18; I2 = 27.05%), insulin (WMD = –0.3 µIU mL–1; 95% CI, –0.99 to 0.38; P = .39; I2 = 91.49%), hemoglobin A1c (HbA1c) (WMD = 0.02%, 95% CI, –0.01 to 0.06; P = .21; I2 = 0%) and Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) (WMD = –0.09; 95% CI, –0.25 to 0.06; P = .26; I2 = 73.13%). The nonlinear dose-response analysis showed a significant association between the olive dose and HOMA-IR (P = .024 for nonlinearity). Also, the duration of olive oil intervention showed a significant nonlinear relationship with HOMA-IR (P = .025 for nonlinearity), insulin (P = .002 for nonlinearity), and HbA1c (P = .048 for nonlinearity) in dose-response analysis. Conclusions: Our comprehensive review and meta-analysis of 51 RCTs indicate that olive oil consumption by adults does not significantly affect overall glycemic control. However, a daily dose of 25-50 g significantly improves the HOMA-IR parameter, suggesting a potential benefit for diabetes management. These findings highlight the need for further research to fully understand the practical implications of olive oil consumption in diabetes care. Systematic Review Registration: PROSPERO registration No. CRD42023459523


  • Open Access

    Effects of apple cider vinegar on glycemic control and insulin sensitivity in patients with type 2 diabetes: A GRADE-assessed systematic review and dose–response meta-analysis of controlled clinical trials

    by Donya Arjmandfard, Mehrdad Behzadi, Zahra Sohrabi, Mohsen Mohammadi Sartang

    Background and aims: Diabetes mellitus (DM) is a multifactorial metabolic disorder that affects the body’s ability to regulate blood sugar levels. Apple cider vinegar (ACV) could possibly improve diabetes; nevertheless, evidences provide conflicting results. This study aimed to evaluate the effects of ACV on glycemic profile in type 2 diabetes patients (T2DM) in controlled trials (CTs) by systematically reviewing and dose–response meta-analysis.Methods: The Scopus, PubMed, and Web of Science databases were searched until November 2024 according to a systematic approach. All CTs investigating ACV’s effects on glycemic factors were included. We used a random-effects model to calculate WMDs and 95% confidence intervals (CIs). The present study assessed publication bias, sensitivity analysis, meta-regression, and heterogeneity based on standard methods. We assessed the bias risk of the included studies using Cochrane quality assessments and used GRADE (Grading of Recommendations Assessment, Development, and Evaluation) to calculate evidence certainty. We registered the study protocol at Prospero (no. CRD42023457493).Results: Overall, we included seven studies in this meta-analysis. ACV significantly reduced fasting blood sugar (FBS) (WMD: −21.929 mg/dL, 95% CI: −29.19, −14.67, p < 0.001) and HbA1c (WMD: −1.53, 95% CI: −2.65, −0.41, p = 0.008) and increased insulin (WMD: 2.059 μu/ml, 95% CI: 0.26, 3.86, p = 0.025), while it did not affect hemostatic model assessment for insulin resistance (HOMA-IR). We observed linear and non-linear associations between ACV consumption and FBS levels (p < 0.001). Each 1 mL/day increase in ACV consumption was associated with a-1.255 mg/dL reduction in FBS. Moreover, greater effects on FBS were in dosages >10.Conclusion: ACV had positive effects on FBS and HbA1c in T2DM patients.Systematic Review Registration: The study protocol was registered at Prospero (no. CRD42023457493).


  • The Effect of Chia Seed on Blood Pressure, Body Composition, and Glycemic Control: A GRADE-Assessed Systematic Review and Dose-Response Meta-Analysis of Randomized Controlled Trials

    by Faranak TaghipourSheshdeh, Mehrdad Behzadi, Sara Bashiri, Mohsen Mohammadi-Sartang

    Numerous studies have demonstrated the positive effects on metabolic factors of consuming chia seeds. However, the results of clinical trials have been inconsistent. The aim of this study was to conduct a systematic review and meta-analysis of available randomized controlled trials to explore the effects of chia seed consumption on body weight (BW), body composition, blood pressure, and glycemic control. A comprehensive search was conducted on the Scopus, PubMed, Medline via Ovid, ISI Web of Science, and Scholar Google databases up to August 2023. The outcomes of interest included systolic blood pressure (SBP), diastolic blood pressure (DBP), BW, body mass index (BMI), body fat percentage, waist circumference (WC), fasting blood glucose (FBG), and hemoglobin A1c (HbA1c). Weighted mean difference (WMD) and 95% CIs were used to determine the effect size. A total of 8 eligible studies were included in the analysis. The findings revealed a significant reduction in SBP (WMD: −7.19 mmHg; 95% CI, −10.63 to −3.73; P < .001) and DBP (WMD: −6.04 mmHg, 95% CI, −9.58 to −2.49; P = .001). However, no significant effects were observed on BW, body fat percentage, WC, BMI, FBG, and HbA1c. Subgroup analysis indicated that the effect of chia seed on SBP was significant in participants with a baseline SBP of less than 140 mmHg, but the effect was not dependent on the administered dose. Chia seed consumption has positive effects on SBP and DBP but does not significantly impact BW, body composition, or glycemic parameters. However, the limited amount of data from included studies should be considered as a limitation while interpreting these findings. PROSPERO registration no. CRD42023462575.


  • Effect of Coenzyme Q10 Supplementation on Vascular Endothelial Function: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

    by Shahrzad Daei, Azam Ildarabadi, Sima Goodarzi, Mohsen Mohamadi-Sartang

    Introduction Coenzyme Q10 (CoQ10) has gained attention as a potential therapeutic agent for improving endothelial function. Several randomized clinical trials have investigated CoQ10 supplementation's effect on endothelial function. However, these studies have yielded conflicting results, therefore this systematic review and meta-analysis were conducted. Aim This systematic review and meta-analysis were conducted to assess the effects of CoQ10 supplementation on endothelial factors. Methods A comprehensive search was done in numerous databases until July 19th, 2023. Quantitative data synthesis was performed using a random-effects model, with weight mean difference (WMD) and 95% confidence intervals (CI). Standard methods were used for the assessment of heterogeneity, meta-regression, sensitivity analysis, and publication bias. Results 12 studies comprising 489 subjects were included in the meta-analysis. The results demonstrated significant increases in Flow Mediated Dilation (FMD) after CoQ10 supplementation (WMD: 1.45; 95% CI: 0.55 to 2.36; p < 0.02), but there is no increase in Vascular cell adhesion protein (VCAM), and Intercellular adhesion molecule (ICAM) following Q10 supplementation (VCAM: SMD: − 0.34; 95% CI: − 0.74 to − 0.06; p < 0.10) (ICAM: SMD: − 0.18; 95% CI: − 0.82 to 0.46; p < 0.57). The sensitivity analysis showed that the effect size was robust in FMD and VCAM. In meta-regression, changes in FMD percent were associated with the dose of supplementation (slope: 0.01; 95% CI: 0.004 to 0.03; p = 0.006). Conclusions CoQ10 supplementation has a positive effect on FMD in a dose-dependent manner. Our findings show that CoQ10 has an effect on FMD after 8 weeks of consumption. Additional research is warranted to establish the relationship between CoQ10 supplementation and endothelial function.


  • Almond supplementation on appetite measures, body weight, and body composition in adults: A systematic review and dose‐response meta‐analysis of 37 randomized controlled trials

    by Negar Chahibakhsh, Nastaran Rafieipour, Homan Rahimi, Sepideh RajabiNezhad, Seyed Aref Momeni, Amir Motamedi, Janmohamad Malekzadeh, Shahidul Islam, Mohsen Mohammadi‐Sartang

    Summary: Background and Objective: Almond consumption has an inverse relationship with obesity and factors related to metabolic syndrome. However, the results of available clinical trials are inconsistent. Therefore, we analyzed the results of 37 randomized controlled trials (RCTs) and evaluated the association of almond consumption with subjective appetite scores and body compositions.Methods: Net changes in bodyweight, body mass index (BMI), waist circumference (WC), fat mass (FM), body fat percent, fat‐free mass (FFM), waist‐to‐hip ratio (WHR), visceral adipose tissue (VAT), and subjective appetite scores were used to calculate the effect size, which was reported as a weighted mean differences (WMD) and 95% confidence interval (CI).Results: This meta‐analysis was performed on 37 RCTs with 43 treatment arms. The certainty in the evidence was very low for appetite indices, body fat percent, FFM, VAT, and WHR, and moderate for other parameters as assessed by the GRADE evidence profiles. Pooled effect sizes indicated a significant reducing effect of almond consumption on body weight (WMD: −0.45 kg, 95% CI: −0.85, −0.05, p = 0.026), WC (WMD: −0.66 cm, 95% CI: −1.27, −0.04, p = 0.037), FM (WMD: −0.66 kg, 95% CI: −1.16, −0.17, p = 0.009), and hunger score (WMD: −1.15 mm, 95% CI: −1.98, −0.32, p = 0.006) compared with the control group. However, almond did not have a significant effect on BMI (WMD: −0.20 kg m−2, 95% CI: −0.46, 0.05, p = 0.122), body fat percent (WMD: −0.39%, 95% CI: −0.93, 0.14, p = 0.154), FFM (WMD: −0.06, 95% CI: −0.47, 0.34, p = 0.748), WHR (WMD: −0.04, 95% CI: −0.12, 0.02, p = 0.203), VAT (WMD: −0.33 cm, 95% CI: −0.99, 0.32), fullness (WMD: 0.46 mm, 95% CI: −0.95, 1.88), desire to eat (WMD: 0.98 mm, 95% CI: −4.13, 2.23), and prospective food consumption (WMD: 1.08 mm, 95% CI: −2.11, 4.28). Subgroup analyses indicated that consumption of ≥50 g almonds per day resulted in a significant and more favorable improvement in bodyweight, WC, FM, and hunger score. Body weight, WC, FM, body fat percent, and hunger scores were decreased significantly in the trials that lasted for ≥12 weeks and in the subjects with a BMI < 30 kg/m2. Furthermore, a significant reduction in body weight and WC was observed in those trials that used a nut‐free diet as a control group, but not in those using snacks and other nuts. The results of our analysis suggest that almond consumption may significantly improve body composition indices and hunger scores when consumed at a dose of ≥50 g/day for ≥12 weeks by individuals with a BMI < 30 kg/m2.Conclusion: However, further well‐constructed randomized clinical trials are needed in order ascertain the outcome of our analysis.


  • Effect of carotenoid supplementation on blood pressure in adults: a GRADE-assessed systematic review and dose–response meta-analysis of randomized controlled trials

    by Mehrdad Behzadi, Marzieh Akbarzadeh, Mohsen Mohammadi Sartang, Mohammadreza Rabiee, Mohammad Vesal Bideshki

    Context: Hypertension (HTN) is regarded as a serious public health issue throughout the world. High blood pressure (BP) may be improved by carotenoid supplementation; however, randomized controlled trials (RCTs) provide conflicting evidence. Objective: The aim of this study was to evaluate the effects of carotenoid supplementation on BP in RCTs by systematically review and meta-analysis. Data Sources: A comprehensive literature search was performed in the Scopus, PubMed, and Web of Science databases until October 2023, with no limitation on the date or language of publication. Data Extraction: Studies that evaluated the net effects of carotenoids in the form of supplements on BP in adults were selected. Weighted mean differences (WMDs) and 95% confidence intervals (CIs) were calculated on the basis of a fixed or random-effects model. Sensitivity analysis, meta-regression, publication bias, and heterogeneity were assessed using standard methods. Cochrane quality assessments were used to evaluate the included studies' bias risks. Evidence certainty was calculated using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) framework). Data Analysis: Reports on a total of 19 RCTs involving 1151 participants were included in this review. Carotenoid supplementation significantly reduced the systolic BP (SBP) (WMD, –2.492 mmHg; 95%CI, –4.52, –0.47; P = 0.016) and diastolic BP (DBP) (WMD, –1.60 mmHg; 95%CI, –2.73, –0.47; P = 0.005). Greater effects were observed in Asian participants, those aged >50 years, nonhealthy participants, and participants with a baseline SBP ≥130 mmHg and DBP ≥80 mmHg, at dose >10 mg. Dose–response analysis showed that carotenoid supplementation decreased SBP and DBP levels at doses of, respectively, 0–25 and 0–20 mg/d. Evidence for all SBP, DBP, and heart rate values was high quality. Conclusions: Carotenoid supplementation had a beneficial effect on BP parameters, especially in nonhealthy study participants with high BP baseline levels. PROSPERO registration no: CRD42023402740.


  • The effect of Alpha‐lipoic acid supplementation on endothelial function: A systematic review and meta‐analysis

    by Yahya Jalilpiran, Maryam Hajishafiee, Masoud Khorshidi, Hamid Rezvani, Mohsen Mohammadi‐Sartang, Jamal Rahmani, Seyed Mohammad Mousavi

    There is evidence that alpha‐lipoic acid (ALA) supplementation plays an important role in preventing cardiovascular diseases. However, its effect, specifically, on endothelial function (EF) is unclear. Therefore, this systematic review and meta‐analysis aimed to evaluate the effects of ALA supplementation on EF. Databases including PubMed/Medline, Scopus, and ISI Web of Science were searched to identify eligible publications from inception up to April 2020. Randomized controlled trials assessing the effect of ALA supplementation on flow‐mediated dilation (FMD) levels in adults were included. The pooled results were obtained using the random‐effects model and are expressed as weighted mean differences (WMD) with 95% confidence intervals (CI). Five studies including six effect sizes and 300 participants were included. ALA supplementation significantly increased FMD levels by 2.36% (95% CI: 1.21–3.51; p < .001), compared with the control. Subgroup analyses suggested that the effects of ALA on FMD could be changed by age and health status of the participants. Dose–response analysis also showed that ALA dosage had a significant non‐linear effect on FMD levels. The results showed that ALA supplementation appears to improve the EF. However, the role of ALA supplementation in improving other biomarkers of EF requires further research.